Lots of reports in the last few days about a successful phase 2 trial that looked at Rituxan and Revlimid (sometimes known as R + R) in previously untreated Follicular Lymphoma patients. The results look very promising.
There's no need, I assume, to introduce about Our Old Pal Rituxan. I've written about Revlimid before, but it's worth a reminder:
Revlimid (also known as Lenalidomide) is kind of cool -- it works in a bunch of different ways, so it can potentially be used for lots of different cancers, both liquid and solid. It works, for example, by messing with cancer cells' ability to grow by keeping stromal cells from growing in the bone marrow. These cells are necessary for the cancer cells to grow -- no stromal, no cancer. It can also inhibit new blood vessels from growing, which cuts off a source of food for cancer cells.
This is a treatment with lots of potential.
And apparently, when combined with Rituxan, that potential is reached even more. The study looked at 54 patients (a pretty small sample, but it is a phase 2 study, after all), and a whopping 92.6% (50 out of 54) had a response to the treatment. 72% achieved a complete response.
Those are pretty darn good numbers. Absolutely worth making this a larger phase 3 trial.
In other news from the same company, Revlimid was combined with R-CHOP for patients with Diffuse Large B Cell Lymphoma (a more aggressive type). Similarly excellent results: 98% response rate, with 74% achieving a complete response. It's not Follicular Lymphoma, but I always like to keep an eye out for anything that can help with transformed FL.....
Read about the two studies in stories from Benzinga and PharmaTimes Online.